|
WO2021043905A1
|
|
Vafidemstat for use in treating autism spectrum disorders
|
|
WO2020245381A1
|
|
3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors
|
|
WO2020193631A1
|
|
Combinations of iadademstat for cancer therapy
|
|
WO2020188090A1
|
|
Methods of treating borderline personality disorder
|
|
WO2020188089A1
|
|
Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
|
|
WO2021004610A1
|
|
Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
|
|
CN112040934A
|
|
Stable pharmaceutical formulation
|
|
WO2019110663A1
|
|
1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
|
|
CA3071804A1
|
|
Methods of treating behavior alterations
|
|
WO2018149986A1
|
|
2-(bicyclo-heteroaryl)-isonicotinic derivatives as histone demethylase inhibitors
|
|
EP3535414A1
|
|
Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
|
|
EP3535420A1
|
|
Biomarkers for determining responsiveness to lsd1 inhibitors
|
|
EP3307267A1
|
|
Multiple sclerosis treatment
|
|
WO2017207813A1
|
|
Heteroaryl-carboxylic acids as histone demethylase inhibitors
|
|
WO2018219478A1
|
|
Heteroaryl-carboxamides as histone demethylase inhibitors
|
|
US2019085372A1
|
|
Methods to determine kdm1a target engagement and chemoprobes useful therefor
|
|
KR20180118229A
|
|
Combinations of LSDl inhibitors for use in the treatment of solid tumors
|
|
KR20180117710A
|
|
Combinations of LSD1 inhibitors for the treatment of hematologic malignancies
|
|
WO2017013061A1
|
|
Biomarkers associated with lsd1 inhibitors and uses thereof
|
|
AU2016275702A1
|
|
Biomarkers associated with LSD1 inhibitors and uses thereof
|
